30c to 8c because of noisy hospital and poor protocol, page-36

Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #

First 36 Last

Share
Profile

Follow
nequalsone

341 Posts.

911

21/12/17

21:53

Post #: 29816123
Share

Originally posted by investorgadget ↑

Thanks for the clarification. From my understanding leave-one-out cross validation both trains the algorithm and tests it at the same time. This method calculates the "apparent error", or how we expect it to be in real world. But of course your right, what the FDA/TGA/CE want is the "true error"- which is calculated by double blinding. When sample sizes are small, the apparent error could be quite different to the true error - which is what concerns FDA etc and you are probably right as to say they are not clinically valid tests. However with sample sizes as large as the Australian data, the apparent error should very closely reflect the true error and in fact this particular type of testing is slightly pessimistic - meaning the true error is going to be better (given its a large enough sample).

Happy to hear other opinions on this.

Expand

Good points. The promising results from the Australian studies were achieved on 611 subjects (adult study) and 1,127 subjects (Pediatric study). Bodes well for the clinical trial if your theory about apparent and true error holds.

RAP Price at posting: 7.9¢ Sentiment: Hold Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

HotCopper Highlights for Week 14 – Mesoblast, Cettire, Neurizon & more!

ELT

Elementos publishes robust DFS for Oropesa tin project

PEK

Meet GeoGeorge: The HotCopper poster so accurate he found a career as a senior analyst

Friday's HotCopper Trends: Mesoblast dodges tariffs, Orthocell's FDA tick | April 4, 2025

Federal Budget underwhelms. Here's everything you'll want to know

Week 14 Wrap: Tariffs tank markets as expected; will Rio Tinto ditch LSE?; EU ETFs soar

AUK

Aumake secures exclusive deal with global goat milk brand Kabrita

BTH

Deal done: Instos take control, locking in Bigtincan’s takeover

RBA keeps rates on hold as world awaits Trump tariff fallout

Listen: HotCopper Podcast 008 – Take-off time... or is it more taxiing?

First 36 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

30c to 8c because of noisy hospital and poor protocol, page-36

Top Stories

HotCopper Highlights for Week 14 – Mesoblast, Cettire, Neurizon & more!

Elementos publishes robust DFS for Oropesa tin project

Meet GeoGeorge: The HotCopper poster so accurate he found a career as a senior analyst

Featured News